How do we protect vulnerable patients when there's a workforce shortage? Dr. Pascal Jean-Pierre explores a community-based model of medical education https://t.co/yosvpll2cg #ASCOconnection
BRCA testing for pancreatic cancer patients is already recommended by NCCN. Today's data on Olaparib give even more reason to identify all mutations. Stop by booth 5087 at #ASCO19 to find out how.
Myriad Genetics is committed to advancing personalized medicine and providing oncologists with high-quality genetic information to enhance care for their patients. Stop by booth 5087 at #ASCO19 to learn more.
Important news broke today for patients with pancreatic cancer. Watch more in this video with Myriad’s chief medical officer, Dr. Johnathan Lancaster. #ASCO19
NCCN Guidelines now recommend hereditary cancer genetic testing for all pancreatic cancers. This is a big reason why... #ASCO19@MyriadMyRisk@myriadgenetics
NCCN Guidelines now recommend hereditary cancer genetic testing for all pancreatic cancers. This is a big reason why... #ASCO19@MyriadMyRisk@myriadgenetics
ICYMI, Myriad’s BRACAnalysis CDx® test identifies patients with metastatic pancreatic cancer who benefited from treatment with Lynparza®. Learn more: https://t.co/D09B34nawQ #ASCO19
Dr Cliff Hudis, ASCO and CCF CEO announces 17 endowed Young Investigator Awards have been funded and will be given out this year! Helping brilliant young doctors get their careers started will ensure new breakthroughs for future cures.
While prostate cancer isn’t (yet) considered to be a Lynch syndrome-associated cancer in NCCN Guidelines, there is clearly a subset of men with prostate cancer attributed to Lynch syndrome. #ASCO19@MyriadMyRisk@myriadgenetics
Dr Taplin discusses 3 important abstracts #ASCO19 - men with advanced #prostatecancer are clearly living longer today, but it’s not good enough!
Olaparib may be an option in selected men, BRCA1/2 mutation carriers have the greatest benefit
Come by Board 278 this morning to see our poster “Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.” Abstract 2634 #ASC019@myriadgenetics@MyriadMyChoice